GoKawiilMulti-institution study maps genomic divergence between astrocytomas and oligodendrogliomas
Researchers from 21 institutions, including MD Anderson, Duke, UCSF and Mayo Clinic, generated new whole-genome and whole-exome sequencing data on brain tumor samples, combining them with previously published GLASS and TCGA datasets. The analysis used longitudinal tumor and blood samples sequenced on Illumina NovaSeq platforms to track genomic changes in astrocytomas and oligodendrogliomas over time.
GoKawiil's interpretation of the reporting above, not reported fact.
Pooling sequencing data across many cancer centers and prior consortia like GLASS and TCGA could give researchers a larger, more statistically powerful dataset to detect patterns in how these two glioma subtypes evolve genetically. Such large-scale collaborative genomic efforts may help clarify why astrocytomas and oligodendrogliomas respond differently to treatment, potentially informing future diagnostic or therapeutic strategies, though the practical clinical impact depends on findings not detailed in this methods description.
- Data came from 21 institutions worldwide, combining newly generated and previously published sequencing data.
- Both whole-genome and whole-exome sequencing were performed using Illumina NovaSeq 6000 with 150-bp paired-end reads.
- The study incorporates longitudinal tumor and blood samples to track genomic evolution in glioma subtypes over time.
Source: nature.com — Chowdhury, 2026-10-14
Published there as: “Divergent genomic evolution in astrocytomas and oligodendrogliomas”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.